PD-L1-Targeted Co-Delivery of Two Chemotherapeutics for Efficient Suppression of Skin Cancer Growth.

Movahedi, Fatemeh; Liu, Jie; Sun, Bing; Cao, Pei; Sun, Luyao; Howard, Christopher; Gu, Wenyi; Xu, Zhi Ping.

Afiliação

Movahedi F; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.
Liu J; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.
Sun B; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.
Cao P; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.
Sun L; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.
Howard C; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.
Gu W; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.
Xu ZP; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD 4072, Australia.

Pharmaceutics ; 14(7)2022 Jul 18.

Article em En | MEDLINE | ID: mdl-35890381

Palavras-chave

TOPK inhibitor OTS964; antiworm albendazole; combination cancer therapy; dual targeting delivery; lipid-coated calcium phosphate nanoparticles; programmed death ligand-1 targeting

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article